pentoxifylline has been researched along with Diabetes Mellitus, Adult-Onset in 40 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " We have conducted a double blinded clinical trial to assess the additive effect of pentoxifylline on reduction of proteinuria among patients with type 2 DM under blockade of angiotensin system." | 9.16 | The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial. ( Beladi-Mousavi, SS; Ghorbani, A; Lak, E; Omidvar, B; Vaziri, S, 2012) |
| "Adjunctive treatment with pentoxifylline is not associated with increased platelet inhibitory effects in DM patients with coronary artery disease receiving DAPT." | 9.15 | Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. ( Angiolillo, DJ; Bass, TA; Capodanno, D; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2011) |
| "To compare the relative efficacy of pentoxifylline (PTX) and angiotensin-converting enzyme (ACE) inhibitor, captopril in the treatment of proteinuria of type 2 diabetic patients." | 9.11 | Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus. ( Amini, M; Aminian, T; Aminorroaya, A; Gharavi, M; Janghorbani, M; Rezvanian, H, 2005) |
| "To compare the efficacy of pentoxifylline and captopril on urinary albumin excretion (UAE) rate in non-hypertensive diabetic patients with microalbuminuria." | 9.11 | Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients--a randomized, equivalent trial. ( Guerrero-Romero, F; Rodríguez-Morán, M, 2005) |
| "Our findings suggest that the combination of pentoxifylline with an angiotensin converting enzyme inhibitor in hypertensive type 2 diabetic patients with persistent microalbuminuria causes a significant reduction in urinary albumin excretion and this effect seems independent from blood pressure and glycemic control." | 9.10 | Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. ( Harmankaya, O; Seber, S; Yilmaz, M, 2003) |
| "Pentoxifylline is not an effective treatment for diabetic erectile dysfunction." | 9.08 | Trial of pentoxifylline for diabetic impotence. ( Georgitis, WJ; Merenich, JA, 1995) |
| "Pentoxifylline is in clinical trials for non-alcoholic fatty liver disease and diabetic nephropathy." | 7.78 | Pentoxifylline aggravates fatty liver in obese and diabetic ob/ob mice by increasing intestinal glucose absorption and activating hepatic lipogenesis. ( Bado, A; Eliat, PA; Fautrel, A; Fromenty, B; Lettéron, P; Massart, J; Noury, F; Robin, MA, 2012) |
| "In 1985, investigators reported that four months of pentoxifylline therapy resulted in a significant decrease in proteinuria (46 percent reduction) and plasma fibrinogen concentrations (18 percent reduction) in patients with diabetes." | 7.68 | Effects of pentoxifylline on proteinuria in normotensive patients with diabetes mellitus. ( Karam, JH; Koda-Kimble, MA; White, JR, 1990) |
| "In the same way, 45 patients with NIDDM were divided in 2 subgroups: one of 23 patients with microalbuminuria, and the other of 22 patients with proteinuria." | 6.68 | Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. ( Amato, D; García-Bulnes, G; Guerrero-Romero, F; Paniagua-Sierra, JR; Rodríguez-Morán, M; Salas-Ramírez, M, 1995) |
| "In patients with type 2 diabetes (T2D), concurrent NAFLD might increase the risk of chronic kidney disease and the mortality rate." | 5.43 | Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation. ( Chang, ML; Chao, J; Cheng, HY; Liao, JW; Pao, LH; Peng, WH; Ye, JH, 2016) |
| "Proteinuria was diagnosed in 2003 (DPE 3." | 5.35 | [Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline]. ( Larczyński, W; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Zietkiewicz, M, 2008) |
| " We have conducted a double blinded clinical trial to assess the additive effect of pentoxifylline on reduction of proteinuria among patients with type 2 DM under blockade of angiotensin system." | 5.16 | The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial. ( Beladi-Mousavi, SS; Ghorbani, A; Lak, E; Omidvar, B; Vaziri, S, 2012) |
| "Adjunctive treatment with pentoxifylline is not associated with increased platelet inhibitory effects in DM patients with coronary artery disease receiving DAPT." | 5.15 | Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. ( Angiolillo, DJ; Bass, TA; Capodanno, D; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2011) |
| "To compare the relative efficacy of pentoxifylline (PTX) and angiotensin-converting enzyme (ACE) inhibitor, captopril in the treatment of proteinuria of type 2 diabetic patients." | 5.11 | Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus. ( Amini, M; Aminian, T; Aminorroaya, A; Gharavi, M; Janghorbani, M; Rezvanian, H, 2005) |
| "To compare the efficacy of pentoxifylline and captopril on urinary albumin excretion (UAE) rate in non-hypertensive diabetic patients with microalbuminuria." | 5.11 | Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients--a randomized, equivalent trial. ( Guerrero-Romero, F; Rodríguez-Morán, M, 2005) |
| "Our findings suggest that the combination of pentoxifylline with an angiotensin converting enzyme inhibitor in hypertensive type 2 diabetic patients with persistent microalbuminuria causes a significant reduction in urinary albumin excretion and this effect seems independent from blood pressure and glycemic control." | 5.10 | Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. ( Harmankaya, O; Seber, S; Yilmaz, M, 2003) |
| "Pentoxifylline is not an effective treatment for diabetic erectile dysfunction." | 5.08 | Trial of pentoxifylline for diabetic impotence. ( Georgitis, WJ; Merenich, JA, 1995) |
| " Six of the nine studies reported a significant reduction in proteinuria in pentoxifylline treated patients." | 4.93 | Can Pentoxifylline be used as Adjunct Therapy to ACE Inhibitors and ARBs in Preserving Kidney Function? ( Al-Makki, A; Carson, C; Shepler, B, 2016) |
| "Pentoxifylline is in clinical trials for non-alcoholic fatty liver disease and diabetic nephropathy." | 3.78 | Pentoxifylline aggravates fatty liver in obese and diabetic ob/ob mice by increasing intestinal glucose absorption and activating hepatic lipogenesis. ( Bado, A; Eliat, PA; Fautrel, A; Fromenty, B; Lettéron, P; Massart, J; Noury, F; Robin, MA, 2012) |
| "In 1985, investigators reported that four months of pentoxifylline therapy resulted in a significant decrease in proteinuria (46 percent reduction) and plasma fibrinogen concentrations (18 percent reduction) in patients with diabetes." | 3.68 | Effects of pentoxifylline on proteinuria in normotensive patients with diabetes mellitus. ( Karam, JH; Koda-Kimble, MA; White, JR, 1990) |
| " CTP-499 was well tolerated with no serious or severe adverse events, or adverse events leading to discontinuation." | 2.82 | A First-in-Patient, Multicenter, Double-Blind, 2-Arm, Placebo-Controlled, Randomized Safety and Tolerability Study of a Novel Oral Drug Candidate, CTP-499, in Chronic Kidney Disease. ( Braman, V; Cheng, C; Dao, M; Graham, P; Liu, J; Neutel, J; Sabounjian, L; Shipley, J; Wu, L, 2016) |
| "In 45 patients with type 2 diabetes mellitus (DM), we prospectively analyzed urinary excretion of N-acetyl-beta-glucosaminidase (NAG), a marker of tubular renal damage; the potential relationship with urinary protein excretion; and effects of pentoxifylline (PTF) administration." | 2.71 | Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study. ( Garca, J; Maca, M; Mora, C; Muros, M; Navarro, JF, 2003) |
| "In the same way, 45 patients with NIDDM were divided in 2 subgroups: one of 23 patients with microalbuminuria, and the other of 22 patients with proteinuria." | 2.68 | Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. ( Amato, D; García-Bulnes, G; Guerrero-Romero, F; Paniagua-Sierra, JR; Rodríguez-Morán, M; Salas-Ramírez, M, 1995) |
| "Pentoxifylline treatment did not affect the plasma levels of the 3 other variables, von Willebrand factor, 6-keto prostaglandin F1 alpha and thromboxane B2." | 2.67 | Platelet activation in diabetic patients with asymptomatic atherosclerosis. ( Imano, E; Kamada, T; Kawamori, R; Kodama, M; Matsushima, H; Nishizawa, H; Watarai, T; Yamasaki, Y, 1994) |
| "Pentoxifylline has been shown to improve circulation through partially occluded peripheral vessels and has been postulated to be of potential benefit." | 2.67 | Pentoxifylline in the treatment of distal diabetic neuropathy. ( Cohen, SM; Mathews, T, 1991) |
| "Clonidine was administered to 16 subjects at two dosage levels (0." | 2.67 | Lack of effect of clonidine and pentoxifylline in short-term therapy of diabetic peripheral neuropathy. ( Chomiak, M; Cohen, KL; Lucibello, FE, 1990) |
| "In patients with type 2 diabetes (T2D), concurrent NAFLD might increase the risk of chronic kidney disease and the mortality rate." | 1.43 | Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation. ( Chang, ML; Chao, J; Cheng, HY; Liao, JW; Pao, LH; Peng, WH; Ye, JH, 2016) |
| "Proteinuria was diagnosed in 2003 (DPE 3." | 1.35 | [Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline]. ( Larczyński, W; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Zietkiewicz, M, 2008) |
| "Pentoxifylline was used in the treatment of 90 patients with atherosclerosis-induced chronic peripheral arterial occlusive disease and diabetic vascular disorders in the lower extremities (clinical Fontaine Stages III and IV) for whom surgical reconstructive treatment was not indicated and who had shown inadequate response to previous therapy." | 1.27 | Clinical investigation of the effects of pentoxifylline in patients with severe peripheral occlusive vascular disease. ( Seige, K; Sternitzky, R, 1985) |
| "A long-term trial with oral pentoxifylline ("Trental" 400) in a dosage of 1200 mg per day was carried out in 70 diabetic patients with and without vascular afflictions." | 1.27 | Diabetic retinal vascular complications and erythrocyte filtrability; results of a 2-year follow-up study with pentoxifylline. ( Ferrari, E; Solerte, SB, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (10.00) | 18.7374 |
| 1990's | 10 (25.00) | 18.2507 |
| 2000's | 11 (27.50) | 29.6817 |
| 2010's | 13 (32.50) | 24.3611 |
| 2020's | 2 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Oliveira, JS | 1 |
| Silva, AADN | 1 |
| Dias, FCR | 1 |
| de Oliveira, EL | 1 |
| de Oliveira Filho, EF | 1 |
| Soares, PC | 1 |
| Ferreira, CMO | 1 |
| da Silva Junior, VA | 1 |
| Leehey, DJ | 1 |
| Carlson, K | 1 |
| Reda, DJ | 1 |
| Craig, I | 1 |
| Clise, C | 1 |
| Conner, TA | 1 |
| Agarwal, R | 1 |
| Kaufman, JS | 1 |
| Anderson, RJ | 1 |
| Lammie, D | 1 |
| Huminik, J | 1 |
| Polzin, L | 1 |
| McBurney, C | 1 |
| Huang, GD | 1 |
| Emanuele, NV | 1 |
| Rabizadeh, S | 1 |
| Dehghani Firouzabadi, F | 1 |
| Noshad, S | 1 |
| Esteghamati, S | 1 |
| Afarideh, M | 1 |
| Ghajar, A | 1 |
| Ganji, M | 1 |
| Saadat, M | 1 |
| Heidari, B | 1 |
| Najafi, MT | 1 |
| Nakhjavani, M | 1 |
| Esteghamati, A | 1 |
| Navarro-González, JF | 2 |
| Sánchez-Niño, MD | 1 |
| Donate-Correa, J | 1 |
| Martín-Núñez, E | 1 |
| Ferri, C | 1 |
| Pérez-Delgado, N | 1 |
| Górriz, JL | 1 |
| Martínez-Castelao, A | 1 |
| Ortiz, A | 1 |
| Mora-Fernández, C | 2 |
| Matas-Nadal, C | 1 |
| Fernández-Armenteros, JM | 1 |
| Casanova Seuma, JM | 1 |
| Vilardell, F | 1 |
| Baradad, M | 1 |
| Aguayo-Ortiz, RS | 1 |
| Muros de Fuentes, M | 1 |
| Chahin, J | 1 |
| Méndez, ML | 1 |
| Gallego, E | 1 |
| Macía, M | 1 |
| del Castillo, N | 1 |
| Rivero, A | 1 |
| Getino, MA | 1 |
| García, P | 1 |
| Jarque, A | 1 |
| García, J | 3 |
| He, T | 1 |
| Cooper, ME | 1 |
| Carson, C | 1 |
| Al-Makki, A | 1 |
| Shepler, B | 1 |
| Sabounjian, L | 1 |
| Graham, P | 1 |
| Wu, L | 1 |
| Braman, V | 1 |
| Cheng, C | 1 |
| Liu, J | 1 |
| Shipley, J | 1 |
| Neutel, J | 1 |
| Dao, M | 1 |
| Ye, JH | 1 |
| Chao, J | 1 |
| Chang, ML | 1 |
| Peng, WH | 1 |
| Cheng, HY | 1 |
| Liao, JW | 1 |
| Pao, LH | 1 |
| Laczy, B | 1 |
| Cseh, J | 1 |
| Mohás, M | 1 |
| Markó, L | 1 |
| Tamaskó, M | 1 |
| Koszegi, T | 1 |
| Molnár, GA | 1 |
| Wagner, Z | 1 |
| Wagner, L | 1 |
| Wittmann, I | 1 |
| Renke, M | 1 |
| Rutkowski, P | 1 |
| Tylicki, L | 1 |
| Zietkiewicz, M | 1 |
| Larczyński, W | 1 |
| Rutkowski, B | 1 |
| Massart, J | 1 |
| Robin, MA | 1 |
| Noury, F | 1 |
| Fautrel, A | 1 |
| Lettéron, P | 1 |
| Bado, A | 1 |
| Eliat, PA | 1 |
| Fromenty, B | 1 |
| Ueno, M | 1 |
| Ferreiro, JL | 1 |
| Tomasello, SD | 1 |
| Tello-Montoliu, A | 1 |
| Capodanno, D | 1 |
| Seecheran, N | 1 |
| Kodali, M | 1 |
| Dharmashankar, K | 1 |
| Desai, B | 1 |
| Charlton, RK | 1 |
| Bass, TA | 1 |
| Angiolillo, DJ | 1 |
| Sheck, L | 1 |
| Weissel, M | 1 |
| Ghorbani, A | 1 |
| Omidvar, B | 1 |
| Beladi-Mousavi, SS | 1 |
| Lak, E | 1 |
| Vaziri, S | 1 |
| Bilsborough, W | 1 |
| O'Driscoll, G | 1 |
| Stanton, K | 1 |
| Weerasooriya, R | 1 |
| Dembo, L | 1 |
| Taylor, R | 1 |
| Green, D | 1 |
| Harmankaya, O | 1 |
| Seber, S | 1 |
| Yilmaz, M | 1 |
| Navarro, JF | 3 |
| Mora, C | 3 |
| Muros, M | 2 |
| Maca, M | 1 |
| Garca, J | 1 |
| Aminorroaya, A | 1 |
| Janghorbani, M | 1 |
| Rezvanian, H | 1 |
| Aminian, T | 1 |
| Gharavi, M | 1 |
| Amini, M | 1 |
| Radfar, M | 1 |
| Larijani, B | 1 |
| Hadjibabaie, M | 1 |
| Rajabipour, B | 1 |
| Mojtahedi, A | 1 |
| Abdollahi, M | 1 |
| Rodríguez-Morán, M | 3 |
| Guerrero-Romero, F | 3 |
| González-González, G | 1 |
| Bermúdez-Barba, MV | 1 |
| Medina de la Garza, CE | 1 |
| Tamez-Pérez, HE | 1 |
| Martínez-Martínez, FJ | 1 |
| Georgitis, WJ | 1 |
| Merenich, JA | 1 |
| Paniagua-Sierra, JR | 1 |
| García-Bulnes, G | 1 |
| Salas-Ramírez, M | 1 |
| Amato, D | 1 |
| Kawamori, R | 1 |
| Imano, E | 1 |
| Watarai, T | 1 |
| Nishizawa, H | 1 |
| Matsushima, H | 1 |
| Kodama, M | 1 |
| Yamasaki, Y | 1 |
| Kamada, T | 1 |
| James, SH | 1 |
| Meyers, AM | 1 |
| Shor, NA | 1 |
| Helunenko, AM | 1 |
| Petrunia, AM | 1 |
| Zelenyĭ, II | 1 |
| Gorson, DM | 1 |
| Cohen, SM | 1 |
| Mathews, T | 1 |
| Cohen, KL | 1 |
| Lucibello, FE | 1 |
| Chomiak, M | 1 |
| White, JR | 1 |
| Karam, JH | 1 |
| Koda-Kimble, MA | 1 |
| Ambrus, JL | 1 |
| Stadler, S | 1 |
| Bannerman, R | 1 |
| Ferrari, E | 2 |
| Fioravanti, M | 1 |
| Patti, AL | 1 |
| Viola, C | 1 |
| Solerte, SB | 2 |
| Utiamyshev, RI | 1 |
| Aref'ev, IM | 1 |
| Mazovetskiĭ, AG | 1 |
| Shevchenko, RA | 1 |
| Sternitzky, R | 1 |
| Seige, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CSP #2008 - Pentoxifylline in Diabetic Kidney Disease[NCT03625648] | Phase 4 | 2,510 participants (Anticipated) | Interventional | 2019-11-18 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for pentoxifylline and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Histomorphometric and oxidative evaluation of the offspring's testis from type 2 diabetic female rats treated with metformin and pentoxifylline.
Topics: Animals; Diabetes Mellitus, Type 2; Female; Lipid Peroxidation; Male; Metformin; Oxidative Stress; P | 2022 |
Can Pentoxifylline be used as Adjunct Therapy to ACE Inhibitors and ARBs in Preserving Kidney Function?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellit | 2016 |
21 trials available for pentoxifylline and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomised controlled trial.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Humans; Multicenter S | 2021 |
Beneficial Effects of Pentoxifylline Plus Losartan Dual Therapy in Type 2 Diabetes with Nephropathy.
Topics: Atrial Natriuretic Factor; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dr | 2018 |
Effects of Pentoxifylline on Soluble Klotho Concentrations and Renal Tubular Cell Expression in Diabetic Kidney Disease.
Topics: Adult; Aged; Albuminuria; Animals; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Nephropathie | 2018 |
Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial.
Topics: Aged; Albumins; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Female; Glom | 2015 |
A First-in-Patient, Multicenter, Double-Blind, 2-Arm, Placebo-Controlled, Randomized Safety and Tolerability Study of a Novel Oral Drug Candidate, CTP-499, in Chronic Kidney Disease.
Topics: Administration, Oral; Aged; Aged, 80 and over; Biomarkers; Diabetes Mellitus, Type 2; Double-Blind M | 2016 |
Effects of pentoxifylline and pentosan polysulphate combination therapy on diabetic neuropathy in type 2 diabetes mellitus.
Topics: Albuminuria; Anticoagulants; Autonomic Nervous System; Blood Pressure; Body Mass Index; Creatinine; | 2009 |
Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel.
Topics: Aged; Aspirin; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Diabe | 2011 |
The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Humans; Male; Middle | 2012 |
Effect of lowering tumour necrosis factor-alpha on vascular endothelial function in Type II diabetes.
Topics: Acetylcholine; Analysis of Variance; Brachial Artery; Cross-Over Studies; Diabetes Mellitus, Type 2; | 2002 |
Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients.
Topics: Aged; Albumins; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Blood Pressure; C | 2003 |
Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study.
Topics: Acetylglucosaminidase; Aged; Anti-Inflammatory Agents, Non-Steroidal; Diabetes Mellitus, Type 2; Dia | 2003 |
Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Captopril; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Femal | 2005 |
Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dr | 2005 |
Effects of pentoxifylline on oxidative stress and levels of EGF and NO in blood of diabetic type-2 patients; a randomized, double-blind placebo-controlled clinical trial.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Epidermal Growth Factor; Female; Free Radical Scaven | 2005 |
Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients--a randomized, equivalent trial.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Captopril; Chi-Square Distribution; Diabetes | 2005 |
Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: a double-blind, placebo-controlled randomized trial.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Humans; | 2006 |
Trial of pentoxifylline for diabetic impotence.
Topics: Aged; Analysis of Variance; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; E | 1995 |
Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients.
Topics: Adult; Albuminuria; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Do | 1995 |
Platelet activation in diabetic patients with asymptomatic atherosclerosis.
Topics: Aged; Arteriosclerosis; beta-Thromboglobulin; Blood Pressure; Carotid Arteries; Carotid Artery Disea | 1994 |
Pentoxifylline in the treatment of distal diabetic neuropathy.
Topics: Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; Electromyography; Humans; Mid | 1991 |
Lack of effect of clonidine and pentoxifylline in short-term therapy of diabetic peripheral neuropathy.
Topics: Clonidine; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; Drug Evaluation; H | 1990 |
17 other studies available for pentoxifylline and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Papular spreading necrobiosis lipoidica: a rare clinical presentation of this pathology.
Topics: Aged; Dermoscopy; Diabetes Mellitus, Type 2; Diagnostic Errors; Erythema; Female; Humans; Necrobiosi | 2019 |
Diabetic nephropathy: renoprotective effects of pentoxifylline in the PREDIAN trial.
Topics: Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Free Radi | 2014 |
Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Dyslipidemias; Fa | 2016 |
[Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type | 2008 |
Pentoxifylline aggravates fatty liver in obese and diabetic ob/ob mice by increasing intestinal glucose absorption and activating hepatic lipogenesis.
Topics: Adipocytes; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Biomarkers; Blood | 2012 |
Selenium and the course of mild Graves' orbitopathy.
Topics: Antioxidants; Diabetes Mellitus, Type 2; Glaucoma; Graves Ophthalmopathy; Humans; New Zealand; Pento | 2011 |
Selenium and the course of mild Graves' orbitopathy.
Topics: Antioxidants; Diabetes Mellitus, Type 2; Graves Ophthalmopathy; Humans; Pentoxifylline; Selenium | 2011 |
Microangiopathic hemolytic anemia as a complication of diabetes mellitus.
Topics: Anemia, Hemolytic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Erythro | 1998 |
[Disorders of the blood microcirculation in patients with suppurative-necrotic complications in diabetes mellitus and the approaches to their correction].
Topics: Adult; Aged; Chronic Disease; Combined Modality Therapy; Conjunctiva; Diabetes Mellitus, Type 1; Dia | 1998 |
Reduction of macroalbuminuria with pentoxifylline in diabetic nephropathy. Report of three cases.
Topics: Aged; Aged, 80 and over; Albuminuria; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic | 1998 |
Nephropathy in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Pentoxifylline; Tumor Necrosis Factor-alp | 2000 |
Effects of pentoxifylline on proteinuria in normotensive patients with diabetes mellitus.
Topics: Adult; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Fibrino | 1990 |
Effect of pentoxifylline on carbohydrate metabolism in type II diabetics.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Intermittent Claudication; Pentoxifylline; Theobro | 1990 |
Effects of long-term treatment (4 years) with pentoxifylline on haemorheological changes and vascular complications in diabetic patients.
Topics: Adult; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephrop | 1987 |
[Changes in the rate of surface blood microcirculation studied by photon-correlation spectroscopy in the practical treatment and diagnosis of diabetes mellitus].
Topics: Adolescent; Adult; Aged; Blood Flow Velocity; Conjunctiva; Diabetes Mellitus, Type 1; Diabetes Melli | 1985 |
Clinical investigation of the effects of pentoxifylline in patients with severe peripheral occlusive vascular disease.
Topics: Adult; Aged; Arterial Occlusive Diseases; Arteriosclerosis; Diabetes Mellitus, Type 1; Diabetes Mell | 1985 |
Diabetic retinal vascular complications and erythrocyte filtrability; results of a 2-year follow-up study with pentoxifylline.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopath | 1985 |